肿瘤临床开发中抗体偶联药物的基于风险药代与药物相互作用表征:IQ联盟视角
本文基于IQ联盟ADC数据库(含26个ADC、6种独特载荷)及9个已批准ADC,分析抗体偶联药物(ADC)的药代表征与药物相互作用(DDI)风险。支持早期开发阶段表征ADC偶联物、总抗体和游离载荷三种分析物,后期逐步减少检测种类;游离载荷系统浓度通常过低不足以作为DDI perpetrator,但作为victim的可能性仍存在,并据此开发了数据驱动的风险决策树。
要点
- 早期临床开发应表征ADC偶联物、总抗体和游离载荷三种分析物。
- 后期研究可基于数据逐步减少需检测的分析物种类。
- 游离载荷通常不构成DDI perpetrator,但作为victim的风险仍需评估。
核心结论
- 支持早期阶段表征全部三种分析物、后期逐步减少检测种类的药代表征策略。
- 游离载荷系统浓度通常过低不足以作为DDI perpetrator,但作为victim的可能性仍存在。
研究设计与样本
- IQ联盟成立ADC工作组建立IQ ADC数据库,纳入26个ADC和6种独特载荷。
- 分析IQ数据库数据及9个FDA已批准ADC。
主要发现
- ADC开发中通常需定量ADC偶联物、总抗体和游离载荷三种分析物。
- 后期临床开发中检测全部三种分析物的获益尚不明确。
- 游离载荷释放后被认为表现类似小分子。
关键数值与推荐
- 开发了数据驱动、基于风险的决策树,用于评估循环载荷作为DDI victim的可能性。
临床怎么用
- 早期临床开发阶段应检测ADC偶联物、总抗体和游离载荷。
- 后期研究可基于数据逐步减少分析物检测数量。
- 评估游离载荷作为DDI victim时可采用所开发的决策树。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-drug conjugates (ADCs) represent a rapidly evolving area of drug development and hold significant promise. To date, nine ADCs have been approved by the US Food and Drug Administration (FDA). These conjugates combine the target specificity of monoclonal antibodies with the anticancer activity of small-molecule therapeutics (also referred to as payload). Due to the complex structure, three analytes, namely ADC conjugate, total antibody, and unconjugated payload, are typically quantified during drug development; however, the benefits of measuring all three analytes at later stages of clinical development are not clear. The cytotoxic payloads, upon release from the ADC, are considered to behave like small molecules. Given the relatively high potency and low systemic exposure of cytotoxic payloads, drug-drug interaction (DDI) considerations for ADCs might be different from traditional small molecule therapeutics. The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) convened an ADC working group to create an IQ ADC database that includes 26 ADCs with six unique payloads. The analysis of the ADC data in the IQ database, as well as nine approved ADCs, supports the strategy of pharmacokinetic characterization of all three analytes in early-phase development and progressively minimizing the number of analytes to be measured in the late-phase studies. The systemic concentrations of unconjugated payload are usually too low to serve as a DDI perpetrator; however, the potential for unconjugated payloads as a victim still exists. A data-driven and risk-based decision tree was developed to guide the assessment of a circulating payload as a victim of DDI.
引用
- Li C, Menon R, Walles M, et al. Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. Clin Pharmacol Ther. 2021. PMID: 34657311. doi:10.1002/cpt.2448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。